Of note, one patient was enrolled based on partial MLH1 loss by immunohistochemistry but was found to have MSS disease and low tumor mutational burden (TMB) on MSK-IMPACT testing, suggesting that she actually had MMR-proficient disease. This evidence concerns the gene MLH1 and neoplasm.